Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)

Gelijkaardige items

• Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls
  door: Scheerans, Christian, et al.
  Gepubliceerd in: (2011)
• Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass
  door: Radovits, Tamás, et al.
  Gepubliceerd in: (2009)
• Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
  door: Frey, Reiner, et al.
  Gepubliceerd in: (2013)
• Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
  door: Frey, Reiner, et al.
  Gepubliceerd in: (2013)
• Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  door: Frey, Reiner, et al.
  Gepubliceerd in: (2009)